Adverse effects associated with the intrathecal administration of ziconotide.
The omega-conopeptide, ziconotide, is an N-type calcium-channel blocker that has been shown to produce antinociception in animals using formalin and hot-plate tests. Initial reports of intrathecal administration of ziconotide in cancer and AIDS patients whose pain was unrelieved with opioids demonstrated analgesic efficacy. Although adverse effects were reported, these appeared to be easily managed through dose reduction or symptomatic treatment. This clinical report describes the experiences of three patients with serious adverse effects associated with intrathecal ziconotide.
Penn
R D
RD
Department of Neurosurgery, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY, USA. rpenn@mssm.edu
Paice
J A
JA
D001259:Ataxia / Q000139:chemically induced; D001416:Back Pain / Q000150:complications; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003221:Confusion / Q000139:chemically induced / Q000523:psychology; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007278:Injections, Spinal; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D009759:Nystagmus, Pathologic / Q000139:chemically induced; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D001749:Urinary Bladder Neoplasms / Q000150:complications; D020960:omega-Conotoxins / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D020960:omega-Conotoxins; C078452:ziconotide